Dashboard
1
With ROE of 15.20%, it has a very attractive valuation with a 3.05 Price to Book Value
- Over the past year, while the stock has generated a return of 17.84%, its profits have risen by 16.4% ; the PEG ratio of the company is 1.2
- At the current price, the company has a high dividend yield of 2.3
Stock DNA
Pharmaceuticals & Biotechnology
CNY 72,495 Million (Large Cap)
20.00
NA
2.25%
0.00
15.20%
3.05
Revenue and Profits:
Net Sales:
10,882 Million
(Quarterly Results - Jun 2025)
Net Profit:
889 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
23.88%
0%
23.88%
6 Months
14.54%
0%
14.54%
1 Year
35.1%
0%
35.1%
2 Years
6.22%
0%
6.22%
3 Years
3.06%
0%
3.06%
4 Years
-7.87%
0%
-7.87%
5 Years
83.7%
0%
83.7%
Huadong Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.69%
EBIT Growth (5y)
7.58%
EBIT to Interest (avg)
36.90
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
0.08
Sales to Capital Employed (avg)
1.57
Tax Ratio
17.97%
Dividend Payout Ratio
46.39%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
17.22%
ROE (avg)
14.25%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
3.05
EV to EBIT
16.40
EV to EBITDA
13.50
EV to Capital Employed
3.05
EV to Sales
1.71
PEG Ratio
1.23
Dividend Yield
2.25%
ROCE (Latest)
18.59%
ROE (Latest)
15.20%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10,881.80
10,678.50
1.90%
Operating Profit (PBDIT) excl Other Income
1,322.50
1,388.30
-4.74%
Interest
30.20
25.90
16.60%
Exceptional Items
0.00
0.00
Consolidate Net Profit
889.30
914.00
-2.70%
Operating Profit Margin (Excl OI)
97.80%
105.90%
-0.81%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1.90% vs 3.26% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -2.70% vs -1.89% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
41,655.10
40,391.20
3.13%
Operating Profit (PBDIT) excl Other Income
5,178.90
4,406.20
17.54%
Interest
123.70
144.20
-14.22%
Exceptional Items
2.90
-7.00
141.43%
Consolidate Net Profit
3,494.20
2,846.40
22.76%
Operating Profit Margin (Excl OI)
103.60%
88.80%
1.48%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 3.13% vs 7.69% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 22.76% vs 12.39% in Dec 2023
About Huadong Medicine Co., Ltd. 
Huadong Medicine Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






